Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206518 · ClinicalTrials.gov registry record · Phase 2
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
A Phase 2 study, sponsored by Mothaffar Rimawi.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00206518: Completed Phase 2 study, sponsored by Mothaffar Rimawi.
NCT00206518 is a Phase 2 study that has completed, run by Mothaffar Rimawi. The registered enrollment target is 167 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206518, a Phase 2 study, has completed, sponsored by Mothaffar Rimawi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.
Interventions
- DRUG doxorubicin
- DRUG Taxotere/Docetaxel
- DRUG Adriamycin/Cytoxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2004-09 |
| Est. Completion | 2016-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206518
The ClinicalTrials.gov registry entry for NCT00206518 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mothaffar Rimawi, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which doxorubicin is the first listed.
NCT00206518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206518 about?
NCT00206518 is a clinical study titled "Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients". The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.
What is the current status of trial NCT00206518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2004-09. Estimated completion is 2016-10-10.
What interventions are being tested in trial NCT00206518?
The interventions under investigation include: doxorubicin (DRUG), Taxotere/Docetaxel (DRUG), Adriamycin/Cytoxan (DRUG).
Who is sponsoring clinical trial NCT00206518?
This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.